Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 |
filingDate |
2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d38955df137d281de1589228a8688e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96eebe7aea51da7bd3fa9d1bdf0d56d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3168a94ab8a98ebccf0a987c88f93fd7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6443f08da801461e634dc10a9eabbc12 |
publicationDate |
2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11219646-B2 |
titleOfInvention |
Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
abstract |
Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019183936-A1 |
priorityDate |
2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |